If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
17 March 2022 With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
17 February 2022 Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.
17 March 2022 With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
17 February 2022 Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.
17 March 2022 With evidence of antimicrobial resistance increasing, can innovation incentives drive pharma to fight back? Donald McNab and Mark Schuster of Marks & Clerk explore.
17 February 2022 Pfizer has sued Teva Pharmaceuticals, alleging that the Israeli pharma company is planning on releasing a generic of Pfizer’s Xeljanz XR arthritis treatment before the branded drug’s key patent expires.
